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bstract
Synovial (diarthrodial) joints are employed within the body to provide skeletal mobility and have a characteristic structure adapted
o provide a smooth almost frictionless surface for articulation. Pathologies of the synovial joint are an important cause of patient
orbidity and can affect each of the constituent tissues. A common feature of these pathologies is degenerative changes in the structure
f the tissue which is mediated, at least in part, by proteolytic activity. Most tissues of the synovial joint are composed primarily
f extracellular matrix and key pathological roles in the degeneration of this matrix are performed by metalloproteinases such
s matrix metallproteinases (MMPs) and a disintegrin and metalloproteinase with thrombospondin motifs (ADAMTS). However,
ther proteases such as cathepsin K are likely to play an important role, especially in bone turnover. In addition to the cleavage of
tructural proteins, proteolytic activities are employed to regulate the activity of other proteases, growth factors, cytokines and other
nflammatory mediators. Proteases combine to form complex regulatory networks, the correct functioning of which is required for
issue homeostasis and the imbalance of which may be a feature of pathology. A precise understanding of the proteases involved in
hese networks is required for a true understanding of the associated pathology.
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1. Overview
Synovial (diarthrodial) joints are employed within the
body to provide skeletal mobility and have a charac-
teristic structure adapted to provide a smooth, almost
frictionless surface for articulation. To the articulat-
ing surfaces of the bones is attached articular hyaline
cartilage—a highly hydrated tissue resistant to compres-
sion that is maintained by a resident population of cells
called chondrocytes. Surrounding the entire joint, insert-
ing into the bones close to the articulating surface, is a
dense connective tissue known as the fibrous capsule, the
inner surface of which is lined with a specialised layer
of connective tissue cells, synoviocytes, which secrete
synovial fluid rich in hyaluronate into the joint space.
The combination of synovial fluid and hyaline cartilage
provides a smooth friction-free surface for articulation.
This arrangement is stabilised through the combined
influence of the bony configuration of the joint, the lig-
amentous and capsular tissue that bind the bones of the
joint together, and the muscles and tendons controlling
the joint.
Synovial joint pathologies are an important cause
of patient morbidity, particularly within developed
countries. They span a wide clinical range of condi-
tions including arthropathies (e.g. rheumatoid arthritis,
osteoarthritis and spondylarthropies) and soft tissue
pathologies (e.g. tendinopathy, capsulitis), each with a
characteristic presentation and affecting specific tissues
of the joint. However, there is clear overlap in the bio-
chemical changes accompanying different pathologies
and each of the component tissues of the synovial joint
may be affected. A common feature of these pathologies
is degenerative changes in the structure of the affected
tissue(s) and peptidases (proteases) are central mediators
of these processes. Ligament shares structural features
with tendon but clinical referrals are generally concerned
with acute injury rather than chronic pathology.
In concert with regulated synthesis, the controlled
enzymatic cleavage of proteins by proteases is of crit-
ical importance to tissue homeostasis. An indication
of this, based on the analysis of completed genomes,
is the recognition that approximately 2% of the total
genes present within a eukaryotic genome encode. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1213
peptidases (Rawlings & Barrett, 1999). A search of
the Ensembl (http://www.ensembl.org) and MEROPS
(http://www.merops.sanger.ac.uk) databases indicates
that of the 21,858 protein-encoding genes (26,008 genes
in total) identified in the human genome, 612 (2.80%
(2.35%)) were known or predicted to encode peptidases.
A further 115 (0.53% (0.44%)) encode known or pre-
dicted inhibitors of peptidases.
According to the International Union of Biochemistry
and Molecular Biology (IUBMB) classification system
(1992), proteases (mechanistically better described as
peptide bond hydrolases), are grouped by the reac-
tion catalysed. However, the naming and classifying
of proteases by this means is problematic since they
all essentially catalyse the same chemical reaction. In
addition, such a system does not infer any evolutionary
relationship between potentially homologous proteins
(Barrett, 1994). Therefore an alternative classification
based on catalytic mechanism and evolutionary relation-
ship has been proposed and developed (Barrett, 1994),
and is available as the MEROPS database (Rawlings,
Tolle, & Barrett, 2004). Four distinct types of catalytic
mechanism are employed by proteases: serine/threonine,
cysteine, aspartic, and metallo (see Fig. 1) (Barrett,
1994). Within the human genome the mechanistic distri-
bution of proteases is approximately 3% aspartic (Asp),
23% cysteine (Cys), 32% serine (Ser) and 36% met-
allo (Southan, 2001). Amongst these the three largest
families are the chymotrypsin family of serine proteases
(S1), the ubiquitin-specific cysteine proteases (C19)
and the adamalysin metalloproteases (M12) (Southan,
2001).
2. Role of proteases in joint pathologies
This review will concentrate on the roles of proteases
in the arthritidies (a group of pathologies with an over-
lapping spectrum of biochemical changes), specifically
rheumatoid and osteoarthritis, which have been the focus
of a large body of research. The roles of proteases in
the pathological changes observed in each of the major
component tissues will be investigated in turn. The roles
of proteases in tendinopathies, which are often distinct
from arthritides, will also be examined briefly.
G.C. Jones et al. / The International Journal of Biochemistry & Cell Biology 40 (2008) 1199–1218 1201
Fig. 1. Schematic outline of the reaction pathways of the four classes of peptidases. (a) Aspartic reaction mechanism: (1) Substrate binding, (2)
nucleophilic attack by a water molecule on the carbonyl group of the scissile bond resulting in formation of tetrahedral transition state, (3) re-
arrangement of transition state completes hydrolysis and N and C-terminal peptides released. (b) Serine reaction mechanism: (1) Substrate binding,
(2) nucleophilic attack by hydroxyl group of serine on the carbonyl group of the scissile bond resulting in the formation of tetrahedral transition
state, (3) re-arrangement resulting in the formation of an acyl-enzyme intermediate and the release of the C-terminal peptide. A water molecule
then binds into the active site, (4) nucleophilic attack by water on the acyl intermediate resulting in the formation of tetrahedral transition state, (5)
re-arrangement resulting in the release of the N-terminal fragment and reformation of the active site. (c) Cysteine reaction mechanism: (1) Substrate
binding, (2) nucleophilic attack by thiol group of cysteine on the carbonyl group of the scissile bond resulting in the formation of tetrahedral transition
state, (3) re-arrangement resulting in the formation of acyl-enzyme intermediate and the release of the C-terminal peptide. A water molecule then
binds into the active site, (4) nucleophilic attack by water on the acyl intermediate resulting in the formation of tetrahedral transition state, (5)
re-arrangement resulting in the release of the N-terminal fragment and reformation of the active site. (d) Metallo reaction mechanism: (1) substrate
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.1. Arthritides
.1.1. Activation of cellular and molecular
nﬂammationBoth rheumatoid and osteoarthritis display inflamma-
ory properties and are associated with the production
f cytokines such as tumour necrosis factor (TNF)
nd interleukin-1 (IL-1) (Brennan, Maini, & Feldmann,the scissile bond resulting in the formation of a tetrahedral transition
-arrangement resulting in release of C-terminal peptide, (4) release of
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1992; Deleuran et al., 1992; Fernandes, Martel-Pelletier,
& Pelletier, 2002; Hulejova´ et al., 2007). A number of
cytokines are known to exist within tissues in inactive
or sequestered forms that can be cleaved by proteases to
generate functionally active forms. TNF has been impli-
cated as an important regulator of arthritic development
and anti-TNF therapies are effective in treating rheuma-
toid arthritis in the majority of patients (Moreland et
f Bioch1202 G.C. Jones et al. / The International Journal o
al., 1999). TNF can be cleaved to its active form by
the metalloprotease a disintegrin and metalloproteinase
(ADAM)-17, also known as TNF converting enzyme
(TACE), which is reportedly up-regulated in arthritis
(Black et al., 1997; Ohta et al., 2001). IL-1 is a potent
stimulator of cartilage breakdown and is recognized as
a pivotal destructive factor in arthritis (Dayer, 2003;
Pettipher, Higgs, & Henderson, 1986). It is synthe-
sized as a pro-form without a secretion signal peptide
in two forms encoded by different genes, IL-1 and
IL-1. The  form is secreted in an active mature
form and is processed intracellularly by the cysteine
proteinase caspase-1 (interleukin-1 converting enzyme,
ICE) (Thornberry et al., 1992). In contrast, IL-1 is
secreted in its pro-form and can be activated proteolyt-
ically by the cysteine proteinase calpain (Kobayashi et
al., 1990).
Post-traumatic activation of the complement cascade
is associated with the pathophysiology of injured tissue
degradation and repair in general and activation of the
complement cascade has been implicated in inflamma-
tory arthritis and cartilage injury (John, Stahel, Morgan,
& Schulze-Tanzil, 2007; Oleesky, Daniels, Williams,
Amos, & Morgan, 1991). Many of the components of
the complement cascade have been identified within the
synovial fluid and may be derived from synovial cells
or chondrocytes, which have been demonstrated to syn-
thesize many of these components (Bradley et al., 1996;
Gulati, Guc, Lemercier, Lappin, & Whaley, 1994). Infil-
trating leukocytes and the synovial vasculature may also
contribute to the synovial fluid pool of complement.
Complement activation in cartilage may contribute to
pathology by affecting inflammatory responses via C5a
(receptors for which have been identified on chondro-
cytes) and inducing cellular lysis via the formation of the
membrane attack complex (Onuma et al., 2002). Addi-
tion of anti-C5a antibodies to a collagen-induced arthritis
model have been reported to reduce the level of pro-
inflammatory cytokines suggesting that the complement
system represents a positive amplification loop of inflam-
matory cytokine production (Banda et al., 2002). In
rheumatoid arthritis and active osteoarthritis evidence of
complement activation has been observed in the synovial
vasculature and sub-lining matrix, whereas in chronic
osteoarthritic conditions it was not apparent, suggesting
complement activation is a feature of the inflammatory
stage of disease (Konttinen et al., 1996).
Central to the activation of the complement cascade
are a number of serine proteases: C1r, C1s, C2a in the
classical pathway; factor B and factor D in the alter-
native pathway; MASP-1, -2 and -3 and C2a in the
lectin pathway (Walport, 2001). In each case the initia-emistry & Cell Biology 40 (2008) 1199–1218
tion of the cascade requires the formation of multimeric
complexes containing these proteases upon an activating
surface; archetypal surfaces of the classical, alternative
and lectin pathways are ligand-bound antibodies (IgG or
IgM), C3b, and mannose lectins, respectively (Walport,
2001). Extracellular matrix (ECM) components such as
fibromodulin and fibronectin are also reportedly able
to activate complement pathways through interactions
with C1q (Barilla & Carsons, 2000; Sjoberg, Onnerfjord,
Mo¨rgelin, Heinega˚rd, & Blom, 2005), suggesting that in
the arthritides ECM fragments released during pathol-
ogy may provide an activating surface. Consistent
with this mechanism, fibronectin fragments produced
in osteoarthritis are known to accelerate cartilage and
synovial inflammation (Yasuda, 2006). In addition to
its role in complement activation, studies of C1s have
identified proteolytic activity toward ECM components
including type I and II collagens (Yamaguchi, Sakiyama,
Matsumoto, Moriya, & Sakiyama, 1990). Studies of
C1s have shown that it is up-regulated and activated in
rheumatoid arthritis within cartilage and may contribute
to matrix degradation (Nakagawa, Sakiyama et al., 1999)
(Table 1).
2.1.2. Cartilage: chondrocyte apoptosis and
extracellular matrix degradation
A key characteristic and functional change observed
in both osteo- and rheumatoid arthritis is the erosion
of the articular cartilage, which results in a narrowing
of the joint space and the impairment of joint articula-
tion. In addition, chondrocyte apoptosis is a feature of
both osteo- and rheumatoid arthritis and is probably a
contributory factor to the ineffective repair of the tis-
sue (Hashimoto, Ochs, Komiya, & Lotz, 1998a; Kim
& Song, 1999; Lotz, Hashimoto, & Ku¨hn, 1999). The
degree of apoptosis is reported to correlate with the clini-
cal grade of osteoarthritic disease and may be initiated by
loss of cell–matrix interactions as has been demonstrated
in several cell systems (Hashimoto, Takahashi, Amiel,
Coutts, & Lotz, 1998b; Meredith, Fazeli, & Schwartz,
1993). Alternatively, apoptosis may be signalled by Fas
ligand derived from inflammatory cells within the syn-
ovium or by nitric oxide (Kim & Song, 1999; Lotz et al.,
1999). Central to the apoptotic process is a proteolytic
cascade comprising a series of evolutionarily related
caspase cysteine proteases (Fan, Han, Cong, & Liang,
2005). These caspases are present within cells in a latent
pro-form which is activated by auto-proteolysis follow-
ing oligomerization or by proteases such as granzyme
B (Fan et al., 2005). Apoptotic signals such as Fas lig-
and or cellular stress leads to the activation of one or
more apoptotic initiator caspases (caspase-2, -8, -9 or
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Table 1
Summary of proteases identified with signalling roles in joint pathology
Enzyme Class Pathological role Reference
Generation of inflammatory mediators
ADAM17 Metallo TNF activation Black et al. (1997)
Calpain Cys IL-1 activation Kobayashi et al. (1990)
Caspase-1 Cys IL-1 activation Thornberry et al. (1992)
Complement cascade proteases (C1r, C1s,
C2a, factor B, factor D, MASP-1,
MASP-2 and MASP-3)
Ser Pro-inflammatory signalling via
formation of C5a and cell lysis
through formation of membrane
attack complex
Banda et al. (2002), Barilla and
Carsons (2000), Onuma et al. (2002),
Sjoberg et al. (2005)
Cleavage of extracellular matrix components
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10) which in turn activate apoptotic mediator caspases
-3, -6, -7) (Fan et al., 2005). The mediator caspases then
leave cellular proteins that trigger apoptosis (Fan et al.,
005).
Articular cartilage is a predominantly extracellular
issue maintained by the resident chondrocyte cell popu-
ation, which occupies 2–5% of the tissue volume (Poole,
lini, & Hollander, 1995). The major components of the
issue matrix are type II collagen, aggrecan and hyaluro-
an. Type II collagen fibrils confer tensile strength to
he tissue and form a network that gives the tissue struc-
ure. Aggrecan binds hyaluronan to form large, highly
nionic aggregates that attract water and, when restrained
ithin the collagen framework, provide resistance to
ompression (Hardingham, Fosang, & Dudhia, 1994;
iani, Chen, Wu, Yee, & Yang, 2002).
Models of articular pathologies have demonstrated
hat aggrecan breakdown and removal from the tissue is
n early and reversible event in cartilage degeneration
hat is followed by the loss of collagen (van Meurs, van
ent, Holthuysen, Singer et al., 1999; Woolley, 1995).
he reversible nature of aggrecan loss from the tissue
uggests that the key pathological activity is the degra-
ation of type II collagen. However, recent studies have
uggested that aggrecan protects the collagen network
rom proteolysis and have demonstrated that prevention
f aggrecan cleavage diminishes both aggrecan loss and
artilage erosion in arthritic model systems (Little et
l., 2007; Pratta et al., 2003). Aggrecan proteolysis may
herefore be a critical initiating step in these pathologies.
Aggrecan possesses approximately 100 chondroitin
ulphate chains of around 20 kDa in size and up to 60
eratan sulphate chains of 5–15 kDa covalently attached
o its protein core predominantly between the second
nd third of three globular domains (Hardingham et al.,
994; Kiani et al., 2002). The large number of negative
roups associated with the sulphates and hydroxyls ofextracellular matrix Nakagawa, Sakiyama et al. (1999),
Yamaguchi et al. (1990)
the chondroitin sulphate chains attract water molecules
that are functionally important in conferring compres-
sive resistance to the tissue (Hardingham et al., 1994;
Kiani et al., 2002). The N-terminal globular domain
of aggrecan mediates the interaction between aggre-
can and hyaluronan, an interaction that is stabilised by
link protein (Day, 1999). Although numerous proteolytic
cleavages of aggrecan have been identified in vitro, the
most studied are cleavages occurring within the inter-
globular domain (IGD) that separates the N-terminal
globular domains from the main keratan sulphate and
chondroitin sulphate attachment domains. The well-
known “aggrecanase” cleavage site is at Glu373-Ala374
(Lohmander, Neame, & Sandy, 1993; Sandy, Flannery,
Neame, & Lohmander, 1992; Sandy, Neame, Boynton,
& Flannery, 1991). This activity generates a major frag-
ment containing the chondroitin sulphate chains that is
unable to bind hyaluronan and is subsequently lost from
the tissue (Campbell, Roughley, & Mort, 1986).
Members of a phylogenetically related sub-group of
the a disintegrin and metalloproteinase with thrombo-
spondin motifs (ADAMTS) metalloproteases including
ADAMTS-1, -4 (aggrecanase-1) and -5 (aggrecanase-2)
have been identified as possessing aggrecanase activity
and cleave the aggrecan core protein at several glutamyl
bonds (Abbaszade et al., 1999; Jones & Riley, 2005;
Kuno et al., 2000; Tortorella et al., 1999) (Fig. 2). Their
involvement in cartilage aggrecan degradation has been
demonstrated using both cleavage site-specific antibod-
ies and N-terminal sequencing of proteolytic fragments
(Malfait, Liu, Ijiri, Komiya, & Tortorella, 2002; Sandy
& Verscharen, 2001; Vankemmelbeke et al., 2003). In
studies of osteoarthritis ADAMTS-4 and -5 have been
implicated as the responsible aggrecanases on the basis
of mRNA and protein expression and investigations
into their relative contributions in models of arthritis
have recently been conducted in mice using catalytic
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Fig. 2. Schematic representation of the structural and evolutionary relationship of the 19 human ADAMTS gene products. The dendrogram was
calculated using ClustalW 1.7 (Thompson, Higgins, & Gibson, 1994). The structural representation of ADAMTS proteins were adapted from Jones
is show
(bone mand Riley (2005). Where applicable the long form of splice variants
Uegf (epidermal growth factor-related sea urchin protein) and BMP-1
domain knockouts of each gene (Glasson et al., 2004,
2005; Malfait et al., 2002). Both ADAMTS-4 and -5
knockout mice were phenotypically normal and indis-
tinguishable from wild-type littermates, indicating that
each enzyme was dispensable for normal development
(Glasson et al., 2004, 2005; Stanton et al., 2005). In a sur-
gically induced OA model there was a major reduction
in the severity of induced OA in ADAMTS-5 knock-n. PLAC, protease and lacunin domain; CUB, complement C1r/C1s,
orphogenic protein-1).
out mice, but no difference in progression or severity
in ADAMTS-4 knockout mice (Glasson et al., 2004,
2005). In a model of inflammatory arthritis, ADAMTS-
5, but not ADAMTS-4, knockout mice were protected
against aggrecan loss (Stanton et al., 2005). Furthermore,
aggrecanase activity was inducible in articular cartilage
explants from wild-type and ADAMTS-4 knockout mice
but not from ADAMTS-5 knockout littermates (Glasson
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t al., 2004, 2005; Stanton et al., 2005). Together these
tudies suggest that, at least in these mouse models,
DAMTS-5 is primarily responsible for the increased
ggrecanase activity and subsequent development of
rthritis. Although aggrecan is likely to be the major
ubstrate of the aggrecanases in cartilage, it is known
hat other macromolecules can also be cleaved. These
nclude other hyalectins such as versican (Westling et al.,
004) and cartilage oligomeric matrix protein (COMP;
hrombospondin-5) (Dickinson et al., 2003).
The ADAMTS enzymes are multi-domain proteins
hat are synthesized as zymogens but which undergo
onstitutive removal of the pro-domain in the secre-
ory pathway by pro-protein convertases such as furin
Wang et al., 2004). Secreted ADAMTS proteinases
an then undergo additional processing at their C-
erminal end (Cal, Arguelles, Ferna´ndez, & Lo´pez-Otı´n,
001; Flannery et al., 2002; Rodriguez-Manzaneque,
ilchanowski, Dufour, Leduc, & Iruela-Arispe, 2000).
n the case of ADAMTS-4, two such events have been
dentified to date, one resulting in the removal of the
ajority of the spacer region, the other in the removal of
he spacer region and the majority of the cysteine-rich
omain (Flannery et al., 2002). These processing events
ave been shown to alter the activity of ADAMTS-4
gainst aggrecan: the processed ADAMTS-4 acquires
he ability to cleave aggrecan within the interglobular
omain in addition to sites within the CS attachment
egion that are also cleaved by the full-length pro-
einase (Gao et al., 2002, 2004) Although C-terminal
rocessing of ADAMTS-4 has been demonstrated to
ccur through an autocatalytic mechanism (Flannery
t al., 2002), cell-based experiments have suggested
hat such cleavages are mediated by MMP (Gao et al.,
002, 2004). A processing pathway in which the full-
ength mature enzyme is bound at the cell surface and
leaved by membrane-type 4-MMP (MT4-MMP, also
ermed MMP-17) to generate both identified truncated
orms has been proposed (Gao et al., 2004). The pro-
essed form retaining the cysteine-rich domain appears
o be maintained at the cell surface by syndecan-1
hrough interactions with both CS and heparan sul-
hate chains, whereas the shorter form is released into
he medium (Gao et al., 2004). Analagous studies of
DAMTS-5 have not been reported. However, it is
ikely that the regulation of aggrecanase activity through
roteolytic processing of ADAMTS aggrecanases is of
mportance in the arthritides. Processing of this type
as the capacity to transform protease activities from
he relatively benign trimming of the C-terminus of
ggrecan to a more destructive activity capable of disag-
regating aggrecan-hyaluronan complexes through IGDemistry & Cell Biology 40 (2008) 1199–1218 1205
proteolysis, resulting in the loss of aggrecan from the
tissue.
Although the aggrecanase-mediated cleavage of
aggrecan appears to be the initial and functionally most
important activity against aggrecan in pathology a large
number of additional proteinases are capable of cleav-
ing this proteoglycan. These include a number of the
MMPs (Cawston, 1995), the aspartic protease cathep-
sin D (Handley et al., 2001) and the cysteine proteases
cathepsins B, L, K and S (Hou et al., 2001; Nguyen,
Mort, & Roughley, 1990). Within cartilage the apparent
protection of collagen proteolysis conferred by aggrecan
and the requirement of aggrecanase-mediated aggrecan
IGD cleavage for pathological progression may reflect
in part an inability of the tissue to activate MMP whilst
aggrecan aggregates are intact. Consistent with such
a hypothesis, the appearance of MMP-mediated cleav-
ages of the aggrecan IGD correlates with the cleavage
of type II collagen (van Meurs, van Lent, Stoop et al.,
1999).
Link protein is essential for the maintenance of the
hyaluronan-aggrecan framework of cartilage. Without
the presence of link protein, the non-covalent association
of hyaluronan and aggrecan is weakened considerably.
Surprisingly little is known about the metabolism of this
important component of the cartilage ECM. Early stud-
ies demonstrated molecular heterogeneity of link protein
in cartilage (Roughley, Poole, & Mort, 1982), possi-
bly as a result of proteolytic processing. It is known
that certain MMPs have the capacity to degrade link
protein (Nguyen, Murphy, Hughes, Mort, & Roughley,
1993; Nguyen, Murphy, Roughley, & Mort, 1989)
although proteolysis may also involve cellular uptake
(Tester, Ilic, Robinson, & Handley, 1999). Proteolysis
of link protein may also be involved in regulatory path-
ways of matrix homeostasis (Liu, McKenna, & Dean,
2000).
In addition to aggrecan loss, advanced arthritic
pathologies are associated with the cleavage and loss of
type II collagen (Dodge & Poole, 1989). In osteoarthritis
cartilage appears to be lost initially from the superficial
layer (adjacent to the synovial fluid), whereas in RA
damage to the type II collagen is first seen at pericellular
sites adjacent to the subchondral bone and also at sites
immediately adjacent to the invading pannus (Dodge &
Poole, 1989; Poole et al., 1995).
In mature cartilage type II collagen triple helices
are assembled into fibrils that are stabilised by cova-
lent cross-links at the non-helical termini of individual
proteins (Cawston, 1995). Triple helical collagen degra-
dation is associated with an activity, termed collagenase,
which cleaves the triple helical collagen to produce
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characteristic one quarter and three quarter fragments
(Dioszegi, Cannon, & Van Wart, 1995). Five phylogenet-
ically related members of the MMP have been identified
as possessing collagenase activity including the ‘col-
lagenases’ MMP-1, -8 and -13 (collagenase-1, -2 and
-3, respectively) (Dioszegi et al., 1995; Freije et al.,
1994), and MMP-2 and MMP-14 (MT1-MMP) (Aimes
& Quigley, 1995; Ohuchi et al., 1997). These proteases
differ in their specificity for different collagen types;
MMP-1 is most active against type III, MMP-8 is most
active against type I and MMP-13 most active against
type II (Cawston & Wilson, 2006). All of the collage-
nases are present in cartilage pathology and may play
a role in type II collagen degradation (Kevorkian et al.,
2004). Triple helical collagen may also be cleaved by
the cysteine protease cathepsin K, which is unique in
its ability to cleave the triple helical region at multiple
sites and is reportedly up-regulated in chondrocytes in
a mouse osteoarthritis model and in the synovium of
patients with rheumatoid arthritis (Garnero et al., 1998;
Hou et al., 2001, 2002; Morko, So¨derstro¨m, Sa¨a¨ma¨nen,
Salminen, & Vuorio, 2004). Cathepsin K has an acidic
pH optimum although interaction with chondroitin sul-
phate has been shown to stabilise the protein at neutral
pH and may promote accumulation of cathepsin K within
cartilage (Li, Hou, & Bro¨mme, 2000).
Additional proteases may also be involved in type
II collagen degradation through the cleavage of the
non-helical regions where the cross-links are located.
These cleavages destabilise the collagen fibrillar struc-
ture, making the individual helices more susceptible to
cleavage by collagenases and may result in the loss of
tensile properties (Bader, Kempson, Barrett, & Webb,
1981; Poole et al., 1995). Ex vivo models of cartilage
degradation have demonstrated that type II collagen
becomes more extractable (Dodge & Poole, 1989), sug-
gesting that the triple helix cross-links are cleaved, and
have shown that this activity is inhibitable by metallopro-
teinase inhibitors (Mort et al., 1993). This implicates a
MMP, possibly MMP-3 (stromelysin-1) which is highly
expressed in cartilage (Kevorkian et al., 2004), albeit
largely in an inactive proform (Martel-Pelletier et al.,
1994; Mudgett et al., 1998). Other proteinases capa-
ble of cleaving in these non-helical regions include the
neutrophil serine proteases cathepsin G and neutrophil
elastase (Starkey, Barrett, & Burleigh, 1977) and the cys-
teine protease cathepsin B (Burleigh, Barrett, & Lazarus,
1974).With a number of exceptions, most notably the
membrane-type MMP (MT-MMP) proteases, the MMPs
are synthesised as latent pro-enzymes with activity sup-
pressed by the interaction of a pro-domain cysteineemistry & Cell Biology 40 (2008) 1199–1218
residue with the active site zinc atom (Cawston &
Wilson, 2006; Nagase & Woessner, 1999). Physiolog-
ical activation occurs through the cleavage and removal
of the pro-domain and hence proteases are central to
the regulation of downstream MMP activity and tissue
degradation (Milner, Elliott, & Cawston, 2001; Nagase
& Woessner, 1999). In contrast, the MT-MMP possess
a furin recognition sequence at the end of the pro-
domain and are constitutively active at the cell surface.
A number of the MMP function as pro-MMP activating
enzymes, notably MMP-3, which is capable of activating
all three pro-collagenases and pro-MMP-9 (Brinckerhoff
et al., 1990; Kna¨uper, Lo´pez-Otin, Smith, Knight, &
Murphy, 1996; Miyazaki et al., 1992; Murphy, Cockett,
Stephens, Smith, & Docherty, 1987). Studies of MMP-
3 knockout mice suggest that MMP-3 is an important
activator of MMP activities in cartilage and that the
absence of MMP-3 significantly reduces tissue degra-
dation in arthritic disease models (van Meurs, van Lent,
Holthuysen, Lambrou et al., 1999; van Meurs, van Lent,
Stoop et al., 1999). Pro-MMP-3 can be activated by the
serine protease plasmin (which must itself be activated
by proteolysis of its pro-form, plasminogen, by proteases
such as the plasminogen activators, which are themselves
secreted in a latent pro-form; Cesarman-Maus & Hajjar,
2005) or the cysteine protease cathepsin B (Milner et al.,
2001; Murphy, Ward, Gavrilovic, & Atkinson, 1992).
Cathepsin B is also able to activate pro-urokinase plas-
minogen activator and may be an important initiator of
the proteolytic cascade (Buttle et al., 1993; Kobayashi et
al., 1991). The importance of pro-enzyme activation in
cartilage pathology has been demonstrated in a murine
antigen-induced arthritis model, where the sub-optimal
stimulation of cartilage lead to a reversible loss of aggre-
can degradation and the up-regulation and synthesis of
pro-MMP3 and pro-collagenases (van Meurs, van Lent,
van de Loo et al., 1999). Pro-MMP were retained in
the cartilage matrix and subsequent stimulation of this
‘loaded tissue’ with IL-1 then led to a much more
aggressive proteolysis of aggrecan compared to ‘non-
loaded’ tissue (van Meurs, van Lent, van de Loo et al.,
1999).
Recent assays of metalloprotease mRNA expres-
sion in normal and arthritic cartilage from the femoral
head has revealed a number of differences including a
decrease in MMP-1 and -3 in pathology compared to
normal and increase in MMP-2, -9 and -13 (Kevorkian
et al., 2004). In addition a number of novel differences
were identified, most notably an increase in MMP-28
and ADAMTS-16 in pathology. The roles of these two
proteases in either normal or pathological cartilage are
not known, but are under investigation (Table 2).
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Table 2
Summary of proteases with pathological roles in cartilage
Enzyme Class Pathological role Reference
Chondrocyte apoptosis
Caspase cascade (caspase-2, -3, -6, -7, -8, -9, -10) Cys Induction of chondrocyte apoptosis Fan et al. (2005),
Hashimoto et al. (1998a),
Kim and Song (1999),
Lotz et al. (1999)
Degradation of cartilage proteoglycans
ADAMTS-1, -4, -5 and MMP Metallo Aggrecan cleavage Abbaszade et al. (1999),
Jones and Riley (2005),
Kuno et al. (2000),
Tortorella et al. (1999)
Cathepsin D Asp Aggrecan cleavage Handley et al. (2001)
Cathepsin B, L, K, S Cys Aggrecan cleavage Hou et al. (2001), Nguyen
et al. (1990)
ADAMTS-5 Metallo Pathological cleavage of aggrecan IGD Glasson et al. (2004,
2005), Stanton et al.
(2005)
ADAMTS-1, -4 Metallo Versican cleavage Sandy et al. (2001)
Degradation of triple helical collagen
MMP-1, -2, -8, -13, -14 (MT1-MMP) Metallo Cleavage of triple helical type II collagen Aimes and Quigley
(1995), Dioszegi et al.
(1995), Freije et al.
(1994), Ohuchi et al.
(1997)
Cathepsin B, K Cys Cleavage of triple helical type II collagen Burleigh et al. (1974),
Garnero et al. (1998),
Hou et al. (2001)
MMP Metallo Cleavage of triple helical collagen
cross-links
Mort et al. (1993)
Cathepsin G, neutrophil elastase Ser Cleavage of triple helical collagen
cross-links
Starkey et al. (1977)
Proteinase activation
MMP-17 (MT4-MMP) Metallo Processing of ADAMTS-4 Gao et al. (2004)
MMP-3 Metallo Processing of pro-collagenases Brinckerhoff et al. (1990),
Kna¨uper et al. (1996),
Murphy et al. (1987)
Plasmin Ser Processing of pro-MMP-3 Milner et al. (2001)
Cathepsin B Cys Processing of pro-MMP-3, activation of uPA
and tPA
Buttle et al. (1993),
Kobayashi et al. (1991),
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.1.3. Synovium: inﬂammation, hyperplasia,
annus formation and protease up-regulation
The synovial tissue is the primary source of nutri-
nts and signalling factors for cartilage and is therefore
mportant in maintaining the health of the joint. The tis-
ue is organised so that sub-lining cells support a layer
f specialised lining cells, termed synoviocytes, which
ace and maintain the synovial fluid. Two distinct cell
ypes, fibroblast-like synoviocytes and macrophage-like
ells, comprise this synovial membrane.
Inflammation of the synovium (synovitis) is a feature
f both rheumatoid and osteoarthritis and also animalMurphy et al. (1992)
ing of plasminogen to plasmin Cesarman-Maus and
Hajjar (2005)
models of these diseases and is associated with an
increase in vascularisation and an increase in the num-
ber of mast cells within the synovial sub-lining (Benito,
Veale, FitzGerald, van Den Berg, & Bresnihan, 2005;
Lee & Weinblatt, 2001; Mapp et al., 2008; Myers et
al., 1990; Nigrovic & Lee, 2007; Walsh et al., 2007). In
rheumatoid arthritis synovitis is associated with hyper-
plasia of the synoviocytes, an infiltration of mononuclear
cells including B cells, T cells and macrophages into
the synovial sublining, and the formation of a locally
invasive pannus (Lee & Weinblatt, 2001). A number
of studies have shown that in arthritic pathologies the
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synovial expression of a number of proteases, including
MMP collagenases, ADAMTS aggrecanases and MMP-
3, is increased as are the levels of these proteases in
the synovial fluid (Hulejova´ et al., 2007; Smeets et al.,
2003; Tchetverikov et al., 2004; Vankemmelbeke et al.,
2001; Vankemmelbeke, Ilic, Handley, Knight, & Buttle,
1999). In vitro studies have implicated synovium-derived
factors, in particular proinflammatory cytokines (Fell &
Jubb, 1977; Saklatvala, Pilsworth, Sarsfield, Gavrilovic,
& Heath, 1984) and proteases (Vankemmelbeke et
al., 1999, 2001) as mediators of cartilage destruction.
Synovium-derived proteases may contribute directly to
the degradation of cartilage and bone in these pathologies
as discussed elsewhere in this review.
A recent study of a mouse osteoarthritic model
demonstrated that depletion of the macrophage-like syn-
oviocytes prior to disease induction reduced cartilage
damage, suggesting a role for synovial macrophage-
like cells in cartilage pathology (Blom et al., 2007).
In this study macrophage depletion also decreased the
level of MMP-mediated aggrecan IGD cleavage prod-
ucts observed within the synovial fluid and inhibited the
up-regulation of MMP-2, -3 and -9 mRNA in synovium,
inferring that macrophage-like synoviocytes influence
MMP-activity within pathological cartilage.
Mast cells are present in the sub-lining of nor-
mal synovium and increase markedly in the arthritides
where they appear to become activated (Nigrovic & Lee,
2007). The activities of the mast cell serine proteases
tryptase and chymase may directly contribute to matrix
degradation: both proteases are reported to activate pro-
MMP-3 and may therefore be important initiators of
the MMP activation cascade leading to collagenase acti-
vation (Gruber et al., 1989; Lees, Taylor, & Woolley,
1994). Chymase is also reported to activate pro-MMP-1
directly (Lees et al., 1994; Saarinen, Kalkkinen, Welgus,
& Kovanen, 1994). These proteases may also modulate
the pathological process through cytokine activation or
inactivation: chymase can degrade cytokines including
IL-6, IL-13, IL-5 and TNF (Zhao, Oskeritzian, Pozez, &
Schwartz, 2005). In contrast, chymase has been reported
to activate IL-1 (Mizutani, Schechter, Lazarus, Black,
& Kupper, 1991). Mast cells might therefore serve to reg-
ulate the inflammatory response. Mast cells have also
been identified as a source of MMP-9 in rheumatoid
arthritis, which is thought to be important for mast cell
migration through the tissue (Di Girolamo et al., 2006).
The pannus is involved in the erosion of both cartilage
and bone and contains both fibroblast-like synoviocytes
and mononuclear cells (Abeles & Pillinger, 2006); Lee
& Weinblatt, 2001). It has been proposed that within
the pannus the synoviocyte-derived cells are involvedemistry & Cell Biology 40 (2008) 1199–1218
in matrix invasion and degradation, with synovial
fibroblast-like cells the primary mediators of marginal
cartilage destruction (Abeles & Pillinger, 2006). Ero-
sion of bone by pannus is believed to be mediated
primarily by monocyte-derived osteoclasts which are
attracted to the joint and stimulated to differentiate by
pro-inflammatory cytokines (Abeles & Pillinger, 2006;
Mor, Abramson, & Pillinger, 2005; Redlich et al., 2002).
Comparison of active and end-stage rheumatoid arthri-
tis has demonstrated an increased expression of MMP,
including the collagenases MMP-1 and -13 and MMP-
3, by fibroblast-like synoviocytes, the roles of which
in cartilage degradation have already been discussed
(see above) (Smeets et al., 2003). An up-regulation of
cathepsin K in synovial fibroblast-like cells has also
been reported in both rheumatoid and osteoarthritis (Hou
et al., 2001, 2002; Hummel et al., 1998). In rheuma-
toid arthritis cathepsin K-positive cells were observed
in areas of high proliferation within the synovium and at
sites of cartilage and bone degradation (Hou et al., 2001).
Ex vivo studies demonstrated engulfment and internal-
ization of type II collagen by fibroblast-like synoviocytes
at sites of cartilage erosion and its accumulation within
lysosomes in the presence of a cathepsin K inhibitor
(Hou et al., 2001). These studies suggest that fibroblast-
like synoviocytes expressing cathepsin K are important
in the clearance of endocytosed collagen at sites of carti-
lage erosion. The immune cells (B cells, T cells, dendritic
cells and macrophages) of the rheumatoid pannus are
believed to be involved in antigen presentation, antibody
production and cytokine generation. An important role
in antigen presentation has been identified for cathepsin
S, which is involved in both the processing of endocy-
tosed proteins to peptides suitable for presentation and
the cleavage of the invariant chain to CLIP during MHC
class II maturation (Riese et al., 1996; Shi et al., 1999;
Villadangos et al., 1999). Studies of cathepsin S knock-
out mice revealed a decrease in their susceptibility to
collagen-induced arthritis and impaired invariant chain
processing in both dendritic cells and B cells (Nakagawa,
Brissette et al., 1999). This suggests that antigen presen-
tation, mediated by cathepsin S in dendritic cells and B
cells is an important driving factor in the maintenance of
inflammatory arthritis.
Inflammation of the synovium occurs early in arthritic
disease and prior to pannus formation in rheumatoid
arthritis and is associated with fibrin deposition, an influx
of mononuclear cells and an increase in vascularisa-
tion (Lee & Weinblatt, 2001). Cellular infiltration into
the synovium is likely to involve degradation of the
existing stromal matrix and extracellular matrix pro-
teases such as the MMP are likely to be involved in
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uch processes. Furthermore, the increase in cathepsin
producing fibroblast-like cells at sites of synovial vas-
ularisation and angiogenesis may indicate a role for
his protease in the loosening of the matrix to facilitate
ngiogenic growth (Hou et al., 2001, 2002). It has been
roposed that pannus formation in rheumatoid arthritis
s initiated by the formation of fibrin clots within the
ynovial fluid at the synovial surface, which provide a
caffold into which synovial fibroblast-like cells migrate
Sa´nchez-Pernaute et al., 2003). This model proposes
hat, as is observed in other inflammatory conditions
able 3
ummary of proteases with pathological roles in synovium
nzyme Class Pathologic
ynovium-derived proteases leading to degradation of cartilage and bone
ADAMTS Metallo Proteolysis
MMP Metallo Proteolysis
Cathepsin K Cys
odulation of inflammatory cytokines
Chymase Ser Cleavage a
TNF. Proc
ngiogenesis into synovium
Cathepsin K Cys ‘Loosening
annus formation via fibrin clot
Coagulation cascade (culminating in thrombin) Ser Processing
Plasmin Ser Fibrinolys
uPA, tPA Ser Processing
Thrombin Ser Cleavage a
MMP Metallo Cleavage o
that contri
ntigen presentation
Cathepsin S Cys Processing
class II pre
ast cell migration
MMP-9 Metallo Cleavage o
ctivation of proteases
Tryptase, chymase Ser Processing
Chymase Ser Processingemistry & Cell Biology 40 (2008) 1199–1218 1209
(Berckmans et al., 2002), inflammation induces an influx
of plasma components into the synovial fluid including
components of the coagulation cascade which become
activated; but that in rheumatoid arthritis there is an
imbalance between coagulation and fibrinolysis leading
to the formation and persistence of clots (Andersen &
Gormsen, 1970). The coagulation cascade comprises a
proteolytic activation series of serine protease ending in
thrombin which then cleaves fibrinogen to fibrin (Cirino,
Napoli, Bucci, & Cicala, 2000), whereas fibrinolysis is
mediated by plasmin, which is generated by the activa-
al role Reference
of cartilage aggrecan Vankemmelbeke et al.
(1999, 2001)
of cartilage and bone fibrillar collagen Smeets et al. (2003),Tchetverikov et al. (2004)
Hou et al. (2001)
nd inactivation of IL-5, -6, -13 and
essing and activation of pro-IL-1
Mizutani et al. (1991),
Zhao et al. (2005)
’ of matrix by proteolysis Hou et al. (2001, 2002)
of fibrinogen to fibrin Andersen and Gormsen
(1970), Berckmans et al.
(2002), Cirino et al.
(2000), Sa´nchez-Pernaute
et al. (2003)
is via fibrin cleavage Cesarman-Maus and
Hajjar (2005)
of plasminogen to plasmin Cesarman-Maus and
Hajjar (2005)
nd inactivation of uPA Braat et al. (2000),
Ronday et al. (1996),
Sa´nchez-Pernaute et al.
(2003)
f fibrin generating unusual epitopes
bute to autoimmunity
Bini et al. (1999),
Sa´nchez-Pernaute et al.
(2003)
of proteins to peptides for MHC
sentation
Nakagawa, Brissette et al.
(1999), Riese et al.
(1996), Shi et al. (1999),
Villadangos et al. (1999)
f matrix components Di Girolamo et al. (2006)
of pro-MMP-3 Gruber et al. (1989), Lees
et al. (1994)
of pro-MMP-1 Lees et al. (1994),
Saarinen et al. (1994)
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tion of plasminogen by proteases such as urokinase-type
plasminogen activator (uPA) and tissue plasminogan
activator (Cesarman-Maus & Hajjar, 2005). The imbal-
ance in these processes has been suggested to arise
either due to the cleavage of uPA by thrombin which
generates a proteolytically inactive form or through an
increased expression of inhibitors of fibrinolysis (Braat,
Jie, Ronday, Beekman, & Rijken, 2000; Ronday et al.,
1996; Sa´nchez-Pernaute et al., 2003). It is also suggested
that the persistence of fibrin in synovial fluids results in
MMP-mediated cleavage of fibrin, which may generate
unusual fibrin epitopes that contribute to autoimmunity
(Bini, Wu, Schnuer, & Kudryk, 1999; Sa´nchez-Pernaute
et al., 2003). The role of protease-activated receptors
(PARs) such as the thrombin-activated receptors PAR-1
and -3, and the plasmin receptor PAR-2, in synovium also
merits further investigation (Ferrell et al., 2003; Shin et
al., 1999) (Table 3).
2.1.4. The joint capsule: protease and inﬂammatory
mediator generation
The joint capsule is a collagen-rich structure pop-
ulated primarily by fibroblasts that may be similar in
phenotype to those found in the adjoining synovium
(Kleftogiannis, Handley, & Campbell, 1994). A poten-
tial role for capsular tissue in the arthritides has remained
largely unstudied, despite the possibility that it may
provide a source of mediators of joint damage and
inflammation. The joint capsule is known to be a poten-
tial source of aggrecanase activity (Ilic et al., 2000), and
capsule has the capacity to increase breakdown of carti-
lage proteoglycan in vitro, even when the cartilage tissue
has been killed. This suggests the action of a capsule-
derived aggrecanase on cartilage (Vankemmelbeke et al.,
1999) (Table 4).
2.1.5. Bone: altered metabolism and extracellular
matrix proteolysis
Late-stage rheumatoid arthritis is associated with the
development of bone erosions and osteoporosis, with
multinucleated osteoclasts within the osteolytic lesions
Table 4
Summary of proteases with pathological roles in capsule
Capsule-derived proteases leading to degradation of
cartilage and bone
Enzyme ADAMTS
Class Metallo
Pathological roles Proteolysis of cartilage
aggrecan
Reference Ilic et al. (2000),
Vankemmelbeke et al. (1999)emistry & Cell Biology 40 (2008) 1199–1218
(Eggelmeijer et al., 1993; Ishikawa, Ohno, & Hirohata,
1984; Magaro et al., 1991). Osteoarthritis is associated
with bone sclerosis and collagen type I synthesis and
metabolism (Mansell & Bailey, 1998; Mansell, Tarlton,
& Bailey, 1997; Seibel, Duncan, & Robins, 1989).
Bone is a predominantly extracellular tissue. The
major organic component of bone is type I collagen, fib-
rils of which form the matrix scaffold (Yasuda, Kaleta, &
Bro¨mme, 2005). The major cell types present in bone are
osteoblasts, osteocytes and osteoclasts, which are the cell
types responsible for the synthetic and degradative tissue
processes in response to systemic and local signals.
Osteoclast-mediated bone resorption requires the
attachment of the osteoclast to the bone surface to form
a sealed resorption lacuna followed by demineraliza-
tion of the surface by secretion of protons into the
lacuna and resorption of collagen (Yasuda et al., 2005).
Disease, inhibitor and expression studies identified the
cysteine protease cathepsin K as the critical enzyme for
osteoclast-mediated matrix solubilisation (Drake et al.,
1996; Everts et al., 1992; Hou et al., 1999; Kamiya et
al., 1998). Cathepsin K is highly expressed by osteo-
clasts and, in contrast to other cathepsins, has a potent
activity against helical collagen, possessing an appar-
ently unique ability to cleave the triple helix at multiple
sites (Drake et al., 1996; Garnero et al., 1998).
Inhibitor studies of bone resorption also suggested a
distinct role for one or more MMPs which was dependent
on bone type (Everts et al., 1999). Further studies have
implied that MMP-mediated collagen proteolysis may
be physiologically important in removing any remain-
ing matrix from areas vacated by osteclasts at the end of
the resorption cycle (Everts et al., 2002). This enzyme
appears to be MMP-13 derived from cells other than
osteoclasts (Delaisse´ et al., 2003; Fuller & Chambers,
1995). Furthermore, it has been proposed that MMP-
13-generated collagen fragments are activating factors
of osteoclasts and may influence osteoclast recruitment
(Holliday et al., 1997; Parikka et al., 2001; Zhao, Byrne,
Boyce, & Krane, 1999). A lysosomal cysteine protease
related to the caspases, which is known as aspariginyl
endopeptidase or legumain, has also been implicated
in the control of bone resorption (Choi et al., 1999).
The C-terminal region of this molecule appears to be
the active component and is also known as osteoclast
inhibitory peptide 2. There is no evidence that this activ-
ity is dependent on proteolysis. Rather, there may be a
receptor for this peptide on osteoclast precursors (Choi,
Kurihara, Oba, & Roodman, 2001). Proteolysis of col-
lagen by cathepsin K and MMP collagenase generates
distinct C-terminal fragments (CTx and ICTP, respec-
tively) that are detectable in serum and urine. One report
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uggests that the serum level of the ICTP collagenase
ragment correlates with disease severity in rheuma-
oid arthritis (Hakala, Risteli, Manelius, Nieminen, &
isteli, 1993). This implicates MMP collagenase activity
n the formation of bone erosions in rheumatoid arthritis
nd other arthritides. Inhibitor and gene knockout stud-
es have identified roles for MT1-MMP (MMP-14) in
steoclast migration (Delaisse´ et al., 2003; Engsig et al.,
000; Sato, Foged, & Delaisse´, 1998). MT1-MMP is
ocated on the plasma membrane at the leading edge of
igrating osteoclasts, suggesting that its collagenolytic
ctivity may aid the movement of the osteoclast along
one surfaces (Irie, Tsuruga, Sakakura, Muto, & Yajima,
001), potentially via a Brownian ratchet motor mech-
nism as suggested by studies of MMP-1-mediated
ollagen proteolysis (Saffarian, Collier, Marmer, Elson,
Goldberg, 2004). MT1-MMP-mediated processing
f the v subunit of v3 integrin and shedding of
he adhesion molecule CD44 has also been implicated
n cell migration (Delaisse´ et al., 2003; Deryugina,
atnikov, Postnova, Rozanov, & Strongin, 2002; Kajita
t al., 2001). The proteolytic activity of MMP may also
nfluence osteoclast-mediated bone turnover by affect-
ng cell signalling. For example, MMP-9 activity may
elease TGF from the matrix, resulting in the stimula-
ion of osteoclast chemotaxis (Dallas, Rosser, Mundy, &
onewald, 2002) (Table 5).
.2. Tendinopathies.2.1. Tendon: tenocyte apoptosis and increased
ollagen turnover
The tendon is a predominantly extracellular tissue
he main component of which is type I collagen, which
able 5
ummary of proteases with pathological roles in bone
nzyme Class Pathological role
one resorption
Cathepsin K Cys Cleavage of helical type I co
MMP-13 Metallo Cleavage of matrix from dem
steoclast activation and migration
MMP-13 Metallo Cleavage of type I collagen g
factor for osteoclasts
MMP-14 (MT1-MMP) Metallo Promotes osteoclast migratio
integrin v subunit, shedding
of type I collagen
MMP-9 Metallo Promotes osteoclast chemota
from matrixemistry & Cell Biology 40 (2008) 1199–1218 1211
comprises between 50 and 85% of the tissue dry weight
(Elliott, 1965). The tissue is maintained by a resident
population of fibroblast-like cells called tenocytes. Type
I collagen fibrils are organised into fibres oriented along
the long axis of the tissue, parallel to the predominant
direction of strain, and are surrounded by a thin layer
called the endotenon (Kastelic, Galeski, & Baer, 1978).
Bundles of fibres form fascicles and the whole tendon is
enveloped with a thin surface layer known as the epitenon
(Jo´zsa & Kannus, 1997). Tendons may be surrounded
by sheaths, either: a synovial sheath, typically found
surrounding tendons associated with pulleys across syn-
ovial joints or; paratenon (a condensation of connective
tissue) at sites such as the Achilles tendon (Benjamin,
2004). Sheaths may become inflamed, often as a result
of overuse injury in athletes, and are associated with
tendon pain.
Tendon pathologies occur as either acute or chronic
conditions and are the result of trauma, repeated micro-
trauma, or the insidious process of clinically silent
(pain-free) degeneration (Riley, 2004). A variety of
chronic tendinopathies have been described and encom-
pass ‘spontaneous’ tendon rupture, painful tendinopathy
and calcific tendinitis. Tenocyte apoptosis is a feature of
tendon degeneration and may contribute to pathology by
obstructing repair as described above in arthritic carti-
lage (Tuoheti et al., 2005; Yuan, Murrell, Wei, & Wang,
2002).
Tendon ruptures are often described as spontaneous as
they occur without any preceeding clinical pain, though
a small proportion may be associated with systemic dis-
eases such as rheumatoid arthritis (Astro¨m & Rausing,
1995; Kannus & Jo´zsa, 1991). A number of degenera-
tive changes have been reported including, hypoxia, loss
Reference
llagen Drake et al. (1996), Everts et al.
(1992), Garnero et al. (1998), Hou et
al. (1999), Kamiya et al. (1998)
ineralised zones Delaisse´ et al. (2003), Everts et al.
(2002), Fuller and Chambers (1995)
enerating an activation Holliday et al. (1997), Parikka et al.
(2001)
n via processing of the
of CD44 and cleavage
Delaisse´ et al. (2003), Deryugina et
al. (2002), Engsig et al. (2000), Irie
et al. (2001), Kajita et al. (2001),
Sato et al. (1998)
xis via release of TGF Dallas et al. (2002)
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Table 6
Summary of proteases with pathological roles in tendon
Enzyme Class Pathological role Reference
Tenocyte apoptosis
Caspase cascade (caspase -2, -3, -6, -7, -8, -9, -10) Cys Induction of tenocyte
apoptosis
Fan et al. (2005), Tuoheti et al. (2005),
Yuan et al. (2002)
Inappropriate processing of tendon extracellular matrix
MMP Metallo Extracellular matrix
c
Millar et al. (1998), Riley et al. (2002)of fibrillar collagen structure, glycosaminoglycan accu-
mulation between the collagen fibres and cell rounding
together with an absence of inflammatory cells (Kannus
& Jo´zsa, 1991). Similar changes have been reported
in chronic tendinopathy, including an abnormal fibre
structure and arrangement, focal changes in cellularity,
rounded cells and an increase in proteoglycan content
(Movin, Gad, Reinholt, & Rolf, 1997).
Chronic tendon pathologies are associated with a
small but significant decrease in collagen content, with
an increase in the proportion of type III collagen, rel-
ative to type I (Riley et al., 1994). Analyses of the
type III collagen content and of slow-forming colla-
gen cross-links have indicated that collagen turnover
is increased in chronic pathologies (Bank, TeKoppele,
Oostingh, Hazleman, & Riley, 1999). MMP proteases
have been implicated in this collagen turnover and
comparisons of normal and ruptured tendon have demon-
strated an increase in the amount of active MMP-1, and a
decrease in the amounts of MMP-2 and -3 together with
increased collagen denaturation and turnover (Riley,
2005; Riley et al., 2002). A key role for the inhi-
bition of metalloprotease activity in the development
of tendinopathy is inferred from the effects of the
broad-spectrum metalloprotease inhibitor Marimastat,
which induces tendinopathy by an unknown mechanism
(Millar et al., 1998). Other pharmacologicals, the fluo-
roquinolones, have been associated with tendinopathy
in some patients and have also been shown to modu-
late MMP activity in vitro (Corps et al., 2002; Williams,
Attia, Wickiewicz, & Hannafin, 2000).
A recent assay of metalloprotease mRNA expression
in normal and chronic pathological Achilles tendons has
revealed a number of differences including a decrease in
MMP-3 in both chronic and ruptured pathologies com-
pared to normal and an increase in MMP-1 in ruptured
pathology (Jones et al., 2006). In addition a number
of novel differences were identified, most notably an
increase in ADAM-12 in both chronic and ruptured
pathology and an increase in MMP-23 in chronic painfulleavage
pathology. The roles of these proteases in either nor-
mal or pathological tendon are not known, but are under
investigation (Table 6).
3. Summary
Pathologies of the synovial joint affect all the con-
stituent tissues and protease-mediated degeneration of
these tissues is a common feature. Most tissues of the
joint are composed primarily of ECM and key roles in the
degeneration of this are performed by proteases active
at neutral pH (serine and metallo proteases). However
some proteases with an acidic pH optimum have been
shown to be active at neutral pH under some circum-
stances (Almeida et al., 2001; Berardi et al., 2001; Brix,
Lemansky, & Herzog, 1996; Buck, Karustis, Day, Honn,
& Sloane, 1992; Buttle et al., 1991; Dehrmann, Coetzer,
Pike, & Dennison, 1995) and there is no doubt that the
activity of cathepsin K in the acidic lacunae of osteo-
clasts is crucial to the turnover of the organic matrix of
long bone. MMP collagenases are likely to play a promi-
nent role in the cleavage of cartilage collagens. It appears
that the turnover of cartilage proteoglycans is mediated
by the ADAMTS aggrecanases, with ADAMTS-4 and
-5 being prominent here. Current evidence suggests that
ADAMTS-5 is the key protease in aggrecan breakdown
in animal models of arthritis.
In addition to the cleavage of structural proteins,
proteolytic activities are also employed to regulate
the activities of other proteases. Proteases combine to
form complex regulatory networks, the correct func-
tion of which is required for tissue homeostasis and the
imbalance of which may be an underlying feature of
pathology. There is little doubt that proenzyme activa-
tion and protease inhibition by protease inhibitors are
also key to the successful control of homeostasis. A
precise understanding of the proteases within these net-
works would aid both a true understanding of pathology
and the identification of possible therapeutic interven-
tions.
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